市场调查报告书
商品编码
1416182
基因分型市场-按产品和服务(试剂和试剂盒、仪器、软体、服务)、技术(PCR、定序、微阵列)、应用(诊断和个人化医疗等)、最终用途、全球预测,2023- 2032 年Genotyping Market-By Products & Services (Reagent & Kit, Instrument, Software, Service), Technology (PCR, Sequencing, Microarray), Application (Diagnostics & Personalized Medicine, & Others), End-use, Global Forecast, 2023-2032 |
由于该领域研发活动的加强,2024 年至 2032 年间,全球基因分型市场的CAGR将达到 15.9%。随着基因研究日益融入从医学到农业的各个学科,对先进基因分型技术的需求激增。
例如,2023 年 6 月,Jumpcode Genomics 官员揭露了一项研究结果,展示了使用基于 CRISPR-Cas9 的体外重复去除改进的基因分型。这种创新方法涉及在基因分型之前透过低通定序去除重复片段,Genome Research 发表的题为「基于CRISPR-Cas9 的重复缺失用于复杂植物基因组高通量基因分型」的研究中证明了这一点。 Jumpcode Genetics 执行长 Yaron Hakak 博士强调了该技术在消除基因组定序库中重复元素方面的有效性。正如研究结果所详述,这种方法提高了编码和调控区域基因分型的精确度。
研究人员和生物技术人员寻求更精确、更有效的基因分型方法来揭示遗传复杂性。随着公司努力提供创新的基因分型解决方案,促进个人化医疗、疾病理解和作物改良的突破,这种需求推动了市场。研究和开发的不断增长势头凸显了基因分型在推进科学前沿的关键作用。
整体基因分型市场份额根据产品和服务、应用和地区进行分类。
从2024年到2032年,仪器细分市场将经历重大发展。随着基因分型技术的不断发展,市场对能够实现精确和高通量基因分型的复杂仪器的需求激增。这些仪器,从 PCR 仪到 DNA 定序仪,为研究人员提供了解开遗传复杂性的有效工具。从医疗保健到农业等各个领域越来越多地采用基因分型,凸显了先进仪器在满足准确、快速基因分型解决方案的需求方面的关键作用,从而塑造了基因分型市场的动态。
2024 年至 2032 年,药物基因组学领域的基因分型市场规模将实现显着的CAGR。药物基因组学领域不断扩大。随着个人化医疗日益受到重视,精确基因分型的需求对于了解影响药物反应的个体遗传变异变得至关重要。基因分型在根据患者的基因谱量身订做治疗和优化治疗结果方面发挥关键作用。由于药物基因组学在医疗保健领域的重要性日益增强,对先进基因分型技术的需求持续增长,强调了市场在提供更有效和个性化的医疗干预工具方面的关键作用。
亚太地区基因分型产业从 2024 年到 2032 年将呈现出值得称讚的CAGR。随着亚太国家科学研究和医疗保健进步的激增,对复杂基因分型技术的需求日益增长。该地区不断扩大的生物技术和製药行业,以及不断增加的基因研究倡议,导致对基因分型解决方案的需求增加。
亚太地区在基因组学研究和个人化医疗方面的关键作用凸显了该市场在提供创新基因分型工具以满足该地区研究人员、临床医生和医疗保健从业人员不断变化的需求方面的重要性。例如,2023年11月,GC Genome和MP Group就基因分型服务SNP Genome Health在泰国的商业化签订了合作独家授权协议。根据合约条款,MP Group 将获得 GC Genome 的独家许可,在指定地区推广 Genome Health。作为合作的一部分,GC Genome 将提供在泰国建立基因实验室所需的基本湿实验室技术和专业知识。
Global Genotyping Market will witness 15.9% CAGR between 2024 and 2032, owing to heightened research and development activities in the field. As genetic studies become increasingly integral to various disciplines, from medicine to agriculture, the need for advanced genotyping technologies surges.
For instance, in June 2023, Jumpcode Genomics officials disclosed findings from a study showcasing improved genotyping using CRISPR-Cas9-based in vitro repeat depletion. This innovative approach involves removing repetitive fragments before genotyping with low-pass sequencing, demonstrated in the study titled "CRISPR-Cas9-based repeat depletion for high-throughput genotyping of complex plant genomes," Genome Research published piece. Yaron Hakak, Ph.D., CEO of Jumpcode Genetics, highlights the technology's effectiveness in eliminating repetitive elements from genome sequencing libraries. This method enhances the precision of genotyping in coding and regulatory regions, as detailed in the study's findings.
Researchers and biotechnologists seek more precise and efficient genotyping methods to unravel genetic complexities. This demand propels the market as companies strive to provide innovative genotyping solutions, facilitating breakthroughs in personalized medicine, disease understanding, and crop improvement. The rising momentum in research and development underscores the critical role of genotyping in advancing scientific frontiers.
The overall Genotyping Market share is classified based on the products and services, application, and region.
Instruments segment will undergo significant development from 2024 to 2032. As genotyping technologies continue to evolve, the market witnesses a surge in demand for sophisticated instruments that enable precise and high-throughput genotyping. These instruments, ranging from PCR machines to DNA sequencers, empower researchers with efficient tools for unraveling genetic complexities. The increasing adoption of genotyping in diverse fields, from healthcare to agriculture, underscores the pivotal role of advanced instruments in meeting the demand for accurate and rapid genotyping solutions, shaping the dynamics of the Genotyping Market.
Genotyping market size from the pharmacogenomics segment will register a noteworthy CAGR from 2024 to 2032. Expanding field of pharmacogenomics. As personalized medicine gains prominence, the need for precise genotyping becomes pivotal in understanding individual genetic variations affecting drug responses. Genotyping plays a critical role in tailoring treatments based on patient's genetic profiles and optimizing therapeutic outcomes. The demand for advanced genotyping technologies continues to rise, driven by the growing significance of pharmacogenomics in healthcare, emphasizing the market's crucial role in providing tools that enable more effective and personalized medical interventions.
Asia Pacific genotyping industry will showcase a commendable CAGR from 2024 to 2032. As scientific research and healthcare advancements surge across Asia-Pacific countries, there is a growing need for sophisticated genotyping technologies. The region's expanding biotechnology and pharmaceutical sectors, in line with increasing genetic research initiatives, contribute to the heightened demand for genotyping solutions.
The Asia-Pacific's pivotal role in genomics research and personalized medicine underscores the market's significance in providing innovative genotyping tools to meet the evolving needs of researchers, clinicians, and healthcare practitioners in the region. For instance, in November 2023, GC Genome and MP Group entered into a collaborative and exclusive license agreement for the commercialization of the genotyping service SNP Genome Health in Thailand. Under the terms of the contract, MP Group will be granted an exclusive license from GC Genome to promote Genome Health in the designated territory. GC Genome will provide the essential wet lab technology and expertise required for establishing a genetic laboratory in Thailand as part of this partnership.